stockrow
Saturday 7 November 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
- Revenue
- +35.5%
- EPS
- +141.9%
- Free cash flow
- +118.7%
- Total debt
- −42.0%
Quarter to June 2026, against a year earlier
16.83
0.24
−1.41%
Follow OMER
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 42 | 65 | 30 | — | — | — | — | — | — | — | 97 | (15.3%) | 128 | 221 | 318 | +57.9% | |
| Gross margin, % | 96.61 | 98.34 | 98.29 | 97.63 | (2.19) | 0.00 | 0.00 | — | — | — | 37.57 | (96.6) pt | ||||||
| EBT | (67) | (53) | (140) | (167) | (196) | (192) | (182) | (175) | (180) | (3) | 119 | (29.7%) | ||||||
| EBT margin, % | (160.38) | (82.50) | (467.68) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 121.99 | +160.4 pt | ||||||
| Net income | (67) | (53) | (127) | (84) | (138) | 194 | 47 | (118) | (157) | (3) | 125 | (28.3%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 1.03 | 1.42 | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.35 | n/m | |||||
| Earnings | (1.65) | (1.17) | (2.61) | (1.71) | (2.41) | 3.12 | 0.76 | (1.88) | (2.70) | (0.05) | 1.71 | (32.2%) | ||||||
| Cash flow | (1.27) | (0.80) | (2.14) | (1.21) | (1.75) | (1.76) | (1.38) | 1.19 | (2.56) | (1.83) | (0.95) | +4.1% | ||||||
| Capex | 0.00 | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | (11.8%) | ||||||
| Free cash flow | (1.28) | (0.80) | (2.15) | (1.22) | (1.76) | (1.76) | (1.38) | 1.18 | (2.56) | (1.83) | (0.95) | +4.1% | ||||||
| Book value | (0.93) | (0.06) | (2.06) | (2.20) | (2.11) | 0.38 | 1.37 | (0.40) | (3.14) | (1.91) | (0.71) | +8.4% | ||||||
| Shares, m | 40 | 46 | 49 | 50 | 57 | 62 | 63 | 63 | 58 | 64 | 68 | +5.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 9.84 | 0.0 | |||||
| P/S | 9.82 | 14.16 | 18.12 | 6.24 | 11.07 | — | — | — | — | — | 12.48 | 11.9 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | ||||||
| EV/Sales | 10.64 | 14.16 | 21.08 | 7.14 | 12.49 | — | — | — | — | — | 12.30 | 13.1 | ||||||
| EV/FCF | (8.57) | (25.09) | (6.04) | (13.22) | (9.19) | — | — | — | — | — | (17.40) | (12.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (52) | (36) | (104) | (60) | (100) | (110) | (86) | 75 | (149) | (116) | (69) | +9.5% | |||||
| Capex | 0 | 0 | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (7.1%) | ||||||
| Free cash flow | (52) | (37) | (104) | (60) | (100) | (110) | (87) | 74 | (149) | (116) | (69) | +9.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 44 | 82 | 53 | 48 | 115 | 196 | 307 | 165 | 55 | 138 | 90 | +13.5% | |||||
| Net debt | 34 | 0 | 89 | 101 | 105 | 161 | 120 | 41 | 97 | 37 | (35) | +0.7% | ||||||
| Shareholders’ equity | (37) | (3) | (100) | (109) | (121) | 24 | 86 | (25) | (183) | (121) | (51) | +13.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (114.81) | (58.26) | (119.43) | (72.55) | (86.83) | 64.71 | 9.39 | (24.31) | (47.86) | (1.11) | 51.22 | +113.7 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (58.58) | (49.56) | (629.94) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 209.62 | 265.67 | 246.20 | 80.78 | 120.17 | (400.60) | 86.63 | (388.17) | 151.08 | 2.21 | (89.15) | (207.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 154 | 173 | 236 | 258 | 277 | 213 | 196 | 198 | 202 | 175 | — | +1.4% | |||||
| Revenue/emp, $m | 0.27 | 0.37 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2018 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026
Omeros Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KARD KARDIGAN INC | $1.3B | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| URGN Urogen Pharma | $1.3B | — (loss-making) | — (loss-making) | +223.85% (above 0%: growing) | n/m | +63.95% (above 0%: growing) | 91.57% | 9.36% | Compare |
| OMER Omeros Corporation | $1.2B | 9.8× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | |
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LBRX LB Pharmaceuticals Inc | $1.2B | — (loss-making) | — | — | n/m | −579.03% (below 0%: shrinking) | — | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.2B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $1.2B | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | +106.95% (above 0%: growing) | 97.39% | 0.00% | Compare |
| MNKD MannKind Corporation | $1.2B | — (loss-making) | — (loss-making) | +24.04% (above 0%: growing) | n/m | −267.69% (below 0%: shrinking) | 0.00% | (2.14%) | Compare |
| Median of peers | $1.2B | — | — | +110.61% | — | −65.73% | 45.79% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 4.18m | 17.58m | 759.96 |
| 2024 | 3.76m | 12.37m | 437.17 |
| 2023 | 7.69m | 8.69m | 144.69 |
Ownership
Directors and executive officers, together
10.50%
Gregory A. Demopulos, M.D.
7.70%
BlackRock, Inc.
5.90%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement